The US Food and Drug Administration recently announced it is set to expand the Total Product Lifecycle Advisory Program (TAP) by enrolling devices from the Office of Neurological and Physical Medicine Devices (OHT5) beginning 1 October.
Currently, there are no neurological devices in the program.